Table 4.
Distribution of patients according to self-reported Chagas disease, cardiovascular functional class and NT-ProBNP results in the SaMi-Trop study
| Variables | Valid N | N | Per cent |
|---|---|---|---|
| Chagas disease self-reported | 1.955 | ||
| Yes | 1870 | 95.6 | |
| No | 64 | 3.3 | |
| No response | 21 | 1.1 | |
| Duration of Chagas disease (years) | 1.896 | ||
| >10 | 1179 | 62.2 | |
| 1–10 | 695 | 36.6 | |
| <1 | 22 | 1.2 | |
| Chagas disease in another family member | 1.947 | ||
| Yes | 1384 | 71.1 | |
| No | 384 | 19.7 | |
| Do not know | 179 | 9.2 | |
| Previous treatment for Chagas disease | 1.953 | ||
| Yes | 1008 | 51.6 | |
| No | 873 | 44.7 | |
| Do not know | 72 | 3.7 | |
| Previous use of benznidazole medicine | 1.955 | ||
| No | 1320 | 67.5 | |
| Yes | 492 | 25.2 | |
| Do not know | 143 | 7.3 | |
| NYHA Functional Classification | 1.931 | ||
| I | 1059 | 54.8 | |
| II or more | 872 | 45.2 | |
| NT-ProBNP level, pg/mL | 1.955 | ||
| <300 | 1368 | 70.2 | |
| ≥300 | 581 | 29.8 |
NT-ProBNP, N-terminal of the prohormone brain natriuretic peptide; NYHA, New York Heart Association.